May 19, 2025
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks Th2 Inflammation in House Dust Mite Models of Asthma Prophylactically and Therapeutically
American Thoracic Society (ATS) 2025
Read More
May 17, 2025
Revolutionizing Immunology: Oral Medicines with Biologics-like Activity
American Thoracic Society (ATS) – Respiratory Innovation Summit 2025
Read More
April 17, 2025
Cell Chemical Biology: CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
Kwiatkowski, et al.
Read More
March 8, 2025
Clinical and Translational Science: Pharmacokinetics and Pharmacodynamics of KT-474, a Novel Selective Interleukin-1 Receptor–Associated Kinase 4 (IRAK4) Degrader, in Healthy Adults
Agarwal, et al.
Read More
December 9, 2024
Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Leukemia, and Solid Tumors
American Society of Hematology (ASH) 2024
Other
Read More
December 9, 2024
Molecular Cancer Therapeutics: KT-253, A Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy Than MDM2 Small Molecule Inhibitors
Chutake, et al.
Read More
October 25, 2024
Potent and Selective Oral STAT6 Degrader, KT-621, Inhibits IL-4 and IL-13 Functions in Human Cells and Blocks TH2 Inflammation In Vivo
American College of Allergy, Asthma & Immunology (ACAAI) 2024
Read More
October 24, 2024
Predictive Markers of Response to the MDM2 Degrader KT-253
EORTC-NCI-AACR Symposium 2024
Other
Read More
October 23, 2024
CDK2 Heterobifunctional Degraders Co-Degrade CDK2 and Cyclin E Resulting in Efficacy in CCNE1-Amplified and Overexpressed Cancers
EORTC-NCI-AACR Symposium 2024
Read More
October 23, 2024
The MDM2 Degraders KTX-049 and KT-253 are Highly Active in Wild-type TP53 Merkel Cell Carcinoma
EORTC-NCI-AACR Symposium 2024
Other
Read More